2025
Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes
Ferrante N, Hubbard R, Weinfurtner K, Mezina A, Newcomb C, Furth E, Bhattacharya D, Njei B, Taddei T, Singal A, Hoteit M, Park L, Kaplan D, Re V. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiology And Drug Safety 2025, 34: e70154. PMID: 40328444, PMCID: PMC12055315, DOI: 10.1002/pds.70154.Peer-Reviewed Original ResearchConceptsPositive predictive valueVeterans Health AdministrationExtrahepatic cholangiocarcinomaValidity of diagnostic codesInternational Classification of Diseases for OncologyUS Veterans Health AdministrationConfidence intervalsPharmacoepidemiological studiesICD-O-3Days of diagnosisVA dataHealth AdministrationIntrahepatic cholangiocarcinomaDiagnostic codesHistology codesCholangiocarcinomaUnique patientsInclusion criteriaCholangiocarcinoma subtypesTopography codesPredictive valuePatientsEvaluate medicationsSubtypesEvaluate determinants
2024
Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective
Baptista A, Macedo A, Marreiros A, Coelho A, Perazella M. Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective. Journal Of Clinical Medicine 2024, 13: 4869. PMID: 39201010, PMCID: PMC11355908, DOI: 10.3390/jcm13164869.Peer-Reviewed Original ResearchGlomerular disordersAdverse drug reactionsPotential nephrotoxinsNephrotoxic potentialDrug reactionsDisproportion indexNotifications of adverse drug reactionsAssociated with medicationsAssociated with drug useNephrotoxic drugsOver-the-counter drugsNon-nephrotoxicMethods:</b>Physiopathological mechanismsOver-the-counterNephrotoxic rolePrescribed medicationsSpontaneous notificationsVigiBaseDrug useEvaluate medicationsMedicationMedication useNephrotoxinsDrug
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply